Osama A Sorour1,2, Almyr S Sabrosa1,3, A Yasin Alibhai1, Malvika Arya1, Akihiro Ishibazawa1,4, Andre J Witkin1, Caroline R Baumal1, Jay S Duker1, Nadia K Waheed5. 1. New England Eye Center, Tufts Medical Center, Boston, MA, USA. 2. Ophthalmology Department, Tanta University, Tanta, Egypt. 3. Institute Ophthalmology Rio de Janeiro/Hospital da Gamboa, Rio de Janeiro, Brazil. 4. Department of Ophthalmology, Asahikawa Medical University, Hokkaido, Japan. 5. New England Eye Center, Tufts Medical Center, Boston, MA, USA. nwaheed@tuftsmedicalcenter.org.
Abstract
PURPOSE: To evaluate changes in macular vessel density following intravitreal anti-VEGF injection in patients with diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). METHODS: In this retrospective case series, optical coherence tomography angiography (OCTA) images from 55 eyes of 35 patients with either DME (46 eyes) or PDR (9 eyes) were included. Macular capillary vessel density at the level of the superficial retinal capillary plexus (SCP), deep retinal capillary plexus (DCP) and total retinal capillary plexus (TCP) before and after anti-VEGF treatment was calculated. Longitudinal changes in vessel density following serial anti-VEGF treatment were analyzed in a subset of eyes. RESULTS: Vessel density in the SCP, DCP or TCP was not found to be significantly different after one, two or three intravitreal injections (p > 0.05 for all time points). Subgroup analysis revealed no significant change in the DME and PDR subgroups (all p > 0.05). Multivariate analysis revealed no effect of type of injected anti-VEGF agent or presence of previous treatment on VD measurements (all p > 0.05). There was no correlation between the anatomic response of DME to treatment and VD measurements. CONCLUSIONS: In this study, macular vessel density remained statistically unchanged following up to three intravitreal injections of any anti-VEGF agent. This indicates that there may not be an early effect of anti-VEGF treatment on macular vessel density and its effect on macular perfusion may not be a direct change in microvascular flow.
PURPOSE: To evaluate changes in macular vessel density following intravitreal anti-VEGF injection in patients with diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). METHODS: In this retrospective case series, optical coherence tomography angiography (OCTA) images from 55 eyes of 35 patients with either DME (46 eyes) or PDR (9 eyes) were included. Macular capillary vessel density at the level of the superficial retinal capillary plexus (SCP), deep retinal capillary plexus (DCP) and total retinal capillary plexus (TCP) before and after anti-VEGF treatment was calculated. Longitudinal changes in vessel density following serial anti-VEGF treatment were analyzed in a subset of eyes. RESULTS: Vessel density in the SCP, DCP or TCP was not found to be significantly different after one, two or three intravitreal injections (p > 0.05 for all time points). Subgroup analysis revealed no significant change in the DME and PDR subgroups (all p > 0.05). Multivariate analysis revealed no effect of type of injected anti-VEGF agent or presence of previous treatment on VD measurements (all p > 0.05). There was no correlation between the anatomic response of DME to treatment and VD measurements. CONCLUSIONS: In this study, macular vessel density remained statistically unchanged following up to three intravitreal injections of any anti-VEGF agent. This indicates that there may not be an early effect of anti-VEGF treatment on macular vessel density and its effect on macular perfusion may not be a direct change in microvascular flow.
Authors: Jeffrey G Gross; Adam R Glassman; Lee M Jampol; Seidu Inusah; Lloyd Paul Aiello; Andrew N Antoszyk; Carl W Baker; Brian B Berger; Neil M Bressler; David Browning; Michael J Elman; Frederick L Ferris; Scott M Friedman; Dennis M Marcus; Michele Melia; Cynthia R Stockdale; Jennifer K Sun; Roy W Beck Journal: JAMA Date: 2015-11-24 Impact factor: 56.272
Authors: Rodolfo Mastropasqua; Lisa Toto; Alessandra Mastropasqua; Raffaella Aloia; Chiara De Nicola; Peter A Mattei; Guido Di Marzio; Marta Di Nicola; Luca Di Antonio Journal: Int J Ophthalmol Date: 2017-10-18 Impact factor: 1.779
Authors: Khalil Ghasemi Falavarjani; Nicholas A Iafe; Jean-Pierre Hubschman; Irena Tsui; Srinivas R Sadda; David Sarraf Journal: Invest Ophthalmol Vis Sci Date: 2017-01-01 Impact factor: 4.799
Authors: Thomas S Hwang; Simon S Gao; Liang Liu; Andreas K Lauer; Steven T Bailey; Christina J Flaxel; David J Wilson; David Huang; Yali Jia Journal: JAMA Ophthalmol Date: 2016-04 Impact factor: 7.389
Authors: Alice Y Kim; Zhongdi Chu; Anoush Shahidzadeh; Ruikang K Wang; Carmen A Puliafito; Amir H Kashani Journal: Invest Ophthalmol Vis Sci Date: 2016-07-01 Impact factor: 4.799
Authors: Jonathan F Russell; Hasenin Al-Khersan; Yingying Shi; Nathan L Scott; John W Hinkle; Kenneth C Fan; Cancan Lyu; William J Feuer; Giovanni Gregori; Philip J Rosenfeld Journal: Am J Ophthalmol Date: 2020-03-13 Impact factor: 5.258
Authors: Ahmed Roshdy Alagorie; Muneeswar Gupta Nittala; Swetha Velaga; Brenda Zhou; Alexander M Rusakevich; Charles C Wykoff; SriniVas R Sadda Journal: JAMA Ophthalmol Date: 2020-08-01 Impact factor: 7.389
Authors: Jonathan F Russell; Nathan L Scott; Justin H Townsend; Yingying Shi; Giovanni Gregori; Ashley M Crane; Harry W Flynn; Jayanth Sridhar; Philip J Rosenfeld Journal: Retina Date: 2021-08-01 Impact factor: 3.975
Authors: Furkan Fatih Gulyesil; Sibel Inan; Hamidu Hamisi Gobeka; Mehmet Cem Sabaner; Anar Alizada Journal: Ir J Med Sci Date: 2022-03-23 Impact factor: 1.568